Company Overview More
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2α inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.
CEO: Rosen Ph.D., Terry J.
Market: NYSE
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

RCUS Arcus Biosciences
19.790+0.420+2.17%
YOY
Do not show
Hide blank lines
(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31(Q3)2021/09/30
Assets
Current assets
Cash, cash equivalents and short term investments
46.75% 1.21B -31.47% 499.31M -7.32% 681.3M -32.95% 524.64M
-Cash and cash equivalents
40.62% 548.78M -14.71% 147.91M -- -- -19.12% 179.43M
-Short-term investments
52.23% 664.75M -36.71% 351.39M -- -- -38.42% 345.21M
Receivables
413.49% 32.17M 43882.45% 746.82M -- -- 4.1% 3.07M
-Accounts receivable
461.97% 29.42M 70881.41% 744.6M -- -- -66.23% 871K
-Accrued interest receivable
166.86% 2.75M 243.14% 2.23M -- -- 491.67% 2.2M
Prepaid assets
113.44% 18.53M 185.51% 15.62M -- -- 48.73% 17.57M
Total current assets
50.17% 1.26B 71.48% 1.26B -7.32% 681.3M -31.6% 545.29M
Non current assets
Net PPE
403.74% 136.47M 482.6% 137.42M -- -- 637.52% 64.37M
-Gross PPE
403.74% 136.47M 309.63% 155.15M -- -- 637.52% 64.37M
-Accumulated depreciation
-- -- -24.08% -17.73M -- -- -- --
Investments and advances
122.18% 128.84M 2725.93% 181.99M -- -- 8001.11% 218.73M
Other non current assets
70.02% 13.89M 66.46% 10.74M -- -- 345.3% 10.9M
Total non current assets
199.41% 279.2M 805.09% 330.15M 2347.45% 910.6M 2018.78% 294M
Total assets
65.05% 1.54B 106.13% 1.59B 106.13% 1.59B 3.48% 839.29M
Liabilities
Current liabilities
Payables
-14.79% 20.91M -22.99% 12.08M -- -- 63.16% 13.22M
-accounts payable
-26.28% 18.09M -34.57% 10.26M -- -- 63.16% 13.22M
-Total tax payable
-- 2.82M -- 1.82M -- -- -- --
Current accrued expenses
66.99% 51.03M 86.55% 51.95M -- -- 54.19% 55.1M
Current deferred liabilities
19.77% 89.31M 36.79% 102M -- -- -35.7% 74.34M
Other current liabilities
-- -- -98.54% 52K -- -- -93.89% 209K
Current liabilities
22.11% 161.25M 36.5% 166.08M -- -- -12.28% 142.87M
Non current liabilities
Long term debt and capital lease obligation
680.74% 114.82M 666.82% 116.89M -- -- -- 48.94M
-Long term capital lease obligation
680.74% 114.82M 666.82% 116.89M -- -- -- 48.94M
Non current deferred liabilities
303.02% 456.91M 276.31% 462.22M -- -- -0.98% 94.68M
Other non current liabilities
36.03% 13.87M -48.66% 5.26M -- -- 24.71% 10.2M
Total non current liabilities
323.5% 585.59M 293.99% 584.36M -- -- 48.2% 153.82M
Total liabilities
176.27% 746.85M 177.96% 750.45M 177.96% 750.45M 11.26% 296.68M
Shareholders'equity
Share capital
0% 7K 16.67% 7K -- -- 16.67% 7K
-common stock
0% 7K 16.67% 7K -- -- 16.67% 7K
-Preferred stock
-- 0 -- 0 -- -- -- 0
Retained earnings
14.33% -343.35M 16.1% -275.35M -- -- -100.75% -554.72M
Paid-in capital
7.42% 1.14B 34.63% 1.12B -- -- 33.72% 1.1B
Gains losses not affecting retained earnings
-232900% -4.66M -2965.91% -1.26M -- -- -213.58% -92K
Total stockholders'equity
19.82% 796.58M 67.52% 841.45M 67.52% 841.45M -0.33% 542.61M
Total equity
19.82% 796.58M 67.52% 841.45M 67.52% 841.45M -0.33% 542.61M
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
--Unqualified Opinion----

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%